Shining Light on Diagnosis and Treatment for Patients with Monogenic Kidney Stone Disorders

Released On
April 15, 2021

Expires On
April 15, 2022

Media Type
Internet

Completion Time
90 minutes

Specialty
Geriatric Medicine, Hospitalist, Nephrology, Other, Pediatrics, Primary Care, Urology

Topic(s)
Genetic Disease, Kidney Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

This activity is supported in part by educational grant from Alnylam Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of pediatric nephrologists, adult nephrologists interested in kidney stone disorders, urologists, advanced practice clinicians in the field of nephrology and urology, as well as other HCPs involved in the management of patients with kidney stone disorders.

Program Overview

Monogenic kidney stone disorders often cause recurrent stones that can lead to organ damage and end-stage kidney disease (ESKD). This activity will offer information on patient identification, treatment options, and clinical management strategies. Additionally, faculty will provide insight into the changing treatment landscape for patients with monogenic kidney stone disorders.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the causes and patient demographics of key monogenic kidney stone disorders
  • Recognize the unique symptoms and clinical presentations of patients with primary hyperoxaluria type 1 (PH1)
  • Propose strategies to navigate clinical evaluation and testing useful in the differential diagnosis of PH1 and other monogenic kidney stone disorders
  • Evaluate current clinical management and treatments for patients with key monogenic kidney stone disorders, including PH1
  • Describe investigational treatments with considerations for clinical use for key monogenic kidney stone disorders, including PH1

Faculty

FACULTY_NAME

David J. Sas, DO, MPH

Pediatric Nephrologist
Department of Pediatric and Adolescent Medicine
Mayo Clinic
Rochester, Minnesota

FACULTY_NAME

Michelle A. Baum, MD

Pediatric Nephrologist
Co-Director, Kidney Stone Clinic
Boston Children’s Hospital
Boston, Massachusetts

 

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Faculty

David Sas, DO

  • Contracted Research: (paid to Mayo Clinic) Alnylam, Dicerna

Michelle A. Baum, MD

  • Speakers Bureau: Alnylam
  • Advisory Board: Discerna
  • Contracted Research: Chinook, Dicerna, Orfan, Retrophin Medical

Staff

Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer: has disclosed no financial relationships.

Patricia Brignoni, AKH Director of Operations/Reviewer: has disclosed no financial relationships.

Louis Settembrino, Catalyst Medical Education, Planner, has no relevant financial relationships to disclose.

Deepti Babu, Catalyst Medical Education, Medical Writer, has no relevant financial relationships to disclose.

AKH Inc. and Catalyst planners and reviewers disclosed no financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Instructions for Participation and Credit

Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity.

Disclosure of Unlabeled Use

AKH Inc., Advancing Knowledge in Healthcare requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For questions please contact AKH Inc. at tbrignoni@akhcme.com.